Human KRT19(Keratin 19) ELISA Kit

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 19 (KRT19) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 19 (KRT19) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 19 (KRT19) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Keratin 19 (KRT19) in serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids.

Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Keratin 19 (KRT19) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids with no significant corss-reactivity with analogues from other species.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Keratin 19 (KRT19) in serum, plasma and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Keratin 19 (KRT19) in serum, plasma and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Keratin 19 (KRT19) in serum, plasma and other biological fluids.

Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse Keratin 19 (KRT19) in serum, plasma and other biological fluids.

Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Mouse Keratin 19 (KRT19) in samples from Serum, plasma and other biological fluids. with no significant corss-reactivity with analogues from other species.

Description: A sandwich ELISA kit for detection of Keratin 19 from Human in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Description: Recombinant Human Keratin 19 expressed in: E.coli

Description: Recombinant Mouse Keratin 19 expressed in: E.coli

Description: Recombinant Rat Keratin 19 expressed in: E.coli

Description: A sandwich ELISA kit for detection of Keratin 19 from Mouse in samples from blood, serum, plasma, cell culture fluid and other biological fluids.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19)

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19)

Description: A Rabbit polyclonal antibody against Mouse Keratin 19 (KRT19)

Description: A Rabbit polyclonal antibody against Rat Keratin 19 (KRT19)

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 19 (KRT19)

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with APC.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with Biotin.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with Cy3.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with FITC.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with HRP.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with PE.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with APC.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with Biotin.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with Cy3.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with FITC.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with HRP.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with PE.

Description: Quantitative sandwich ELISA for measuring Human Keratin, type I cytoskeletal 19 (KRT19) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Keratin, type I cytoskeletal 19 (KRT19) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Human Keratin, type I cytoskeletal 19 (KRT19) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitativesandwich ELISA kit for measuring Mouse Keratin, type I cytoskeletal 19 (KRT19) in samples from serum, plasma, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.

Description: Quantitativesandwich ELISA kit for measuring Mouse Keratin, type I cytoskeletal 19(KRT19) in samples from serum, plasma, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 19 (KRT19). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 19 (KRT19). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 19 (KRT19). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 19 (KRT19). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 19 (KRT19). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 19 (KRT19). This antibody is labeled with PE.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with APC-Cy7.

Description: A Mouse monoclonal antibody against Human Keratin 19 (KRT19). This antibody is labeled with APC-Cy7.

Description: A Rabbit polyclonal antibody against Mouse Keratin 19 (KRT19). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Mouse Keratin 19 (KRT19). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Mouse Keratin 19 (KRT19). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Mouse Keratin 19 (KRT19). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Mouse Keratin 19 (KRT19). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Mouse Keratin 19 (KRT19). This antibody is labeled with PE.

Description: A Rabbit polyclonal antibody against Rat Keratin 19 (KRT19). This antibody is labeled with APC.

Description: A Rabbit polyclonal antibody against Rat Keratin 19 (KRT19). This antibody is labeled with Biotin.

Description: A Rabbit polyclonal antibody against Rat Keratin 19 (KRT19). This antibody is labeled with Cy3.

Description: A Rabbit polyclonal antibody against Rat Keratin 19 (KRT19). This antibody is labeled with FITC.

Description: A Rabbit polyclonal antibody against Rat Keratin 19 (KRT19). This antibody is labeled with HRP.

Description: A Rabbit polyclonal antibody against Rat Keratin 19 (KRT19). This antibody is labeled with PE.

Description: Quantitative sandwich ELISA for measuring Mouse Keratin, type I cytoskeletal 19 (KRT19) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Mouse Keratin, type I cytoskeletal 19 (KRT19) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: Quantitative sandwich ELISA for measuring Mouse Keratin, type I cytoskeletal 19 (KRT19) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.

Description: A Rabbit polyclonal antibody against Human, Rat Keratin 19 (KRT19). This antibody is labeled with APC-Cy7.

Description: A Rabbit polyclonal antibody against Mouse Keratin 19 (KRT19). This antibody is labeled with APC-Cy7.

Description: A Rabbit polyclonal antibody against Rat Keratin 19 (KRT19). This antibody is labeled with APC-Cy7.

Description: A sandwich ELISA kit for quantitative measurement of Human CK-19/KRT19 (Cytokeratin 19) in samples from Serum, Plasma, Cell supernatant

Description: A sandwich CLIA kit for quantitative measurement of Human CK-19/KRT19 (Cytokeratin 19) in samples from Serum, Plasma, Cell supernatant

Description: Cytokeratin-19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast.

Description: Cytokeratin-19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast.

Description: Cytokeratin-19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast.

Description: Cytokeratin-19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This mAb reacts with the rod domain of human cytokeratin-19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This mAb reacts with the rod domain of human cytokeratin-19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This mAb reacts with the rod domain of human cytokeratin-19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This mAb reacts with the rod domain of human cytokeratin-19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This Ab reacts with the rod domain of human cytokeratin 19 (CK19), a polypeptide of 40kDa. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This Ab reacts with the rod domain of human cytokeratin 19 (CK19), a polypeptide of 40kDa. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This Ab reacts with the rod domain of human cytokeratin 19 (CK19), a polypeptide of 40kDa. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This Ab reacts with the rod domain of human cytokeratin 19 (CK19), a polypeptide of 40kDa. CK19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Recognizes a protein of 40kDa, identified as cytokeratin-19 (CK19), which is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Anti-CK19 reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Anti-CK19 is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Keratin 19 is a type I keratin. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transiently superficial layer that envelops the developing epidermis. [Wiki]

Description: Keratin 19 is a type I keratin. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transiently superficial layer that envelops the developing epidermis. [Wiki]

Description: Keratin 19 is a type I keratin. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transiently superficial layer that envelops the developing epidermis. [Wiki]

Description: Keratin 19 is a type I keratin. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transiently superficial layer that envelops the developing epidermis. [Wiki]

Description: Cytokeratin 19 is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. Cytokeratin 19 is a type I keratin. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transiently superficial layer that envelops the developing epidermis. The type I cytokeratins are clustered in a region of chromosome 17q12-q21. [Wiki]

Description: Cytokeratin 19 is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. Cytokeratin 19 is a type I keratin. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transiently superficial layer that envelops the developing epidermis. The type I cytokeratins are clustered in a region of chromosome 17q12-q21. [Wiki]

Description: Cytokeratin 19 is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. Cytokeratin 19 is a type I keratin. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transiently superficial layer that envelops the developing epidermis. The type I cytokeratins are clustered in a region of chromosome 17q12-q21. [Wiki]

Description: Cytokeratin 19 is a member of the keratin family. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. Cytokeratin 19 is a type I keratin. The type I cytokeratins consist of acidic proteins which are arranged in pairs of heterotypic keratin chains. Unlike its related family members, this smallest known acidic cytokeratin is not paired with a basic cytokeratin in epithelial cells. It is specifically found in the periderm, the transiently superficial layer that envelops the developing epidermis. The type I cytokeratins are clustered in a region of chromosome 17q12-q21. [Wiki]

Description: This antibody is specific to the rod domain of human Cytokeratin 19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. Cytokeratin 19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Cytokeratin 19 antibody reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Cytokeratin 19 antibody is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This antibody is specific to the rod domain of human Cytokeratin 19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. Cytokeratin 19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Cytokeratin 19 antibody reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Cytokeratin 19 antibody is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This antibody is specific to the rod domain of human Cytokeratin 19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. Cytokeratin 19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Cytokeratin 19 antibody reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Cytokeratin 19 antibody is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: This antibody is specific to the rod domain of human Cytokeratin 19 (CK19), a polypeptide of 40kDa. Its epitope maps between amino acid 312-335. Cytokeratin 19 is expressed in sweat gland, mammary gland ductal and secretory cells, bile ducts, gastrointestinal tract, bladder urothelium, oral epithelia, esophagus, and ectocervical epithelium. Cytokeratin 19 antibody reacts with a wide variety of epithelial malignancies including adenocarcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Perhaps the most useful application is the identification of thyroid carcinoma of the papillary type, although 50%-60% of follicular carcinomas are also labeled. Cytokeratin 19 antibody is a useful marker for detection of tumor cells in lymph nodes, peripheral blood, bone marrow and breast cancer.

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF405S conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), Biotin conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), PerCP conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), RPE conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF594 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), APC conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF680R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), Concentration: 0.2mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF488A conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF660R conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF568 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF543 conjugate, Concentration: 0.1mg/mL

Description: Primary antibody against Cytokeratin 19(KRT19/799 + KRT19/800), CF647 conjugate, Concentration: 0.1mg/mL